# Faeth Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Faeth Therapeutics, Inc.). ## Overview Faeth Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing cancer therapies that target tumor metabolism and signaling pathways. Its lead program, PIKTOR, is an all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. ## Products & services • PIKTOR oral combination therapy for oncology • Serabelisib-based investigational cancer treatment • Sapanisertib-based investigational cancer treatment • Clinical development of tumor metabolism and signaling therapies • Preclinical and clinical-stage oncology pipeline - **Clinical-stage oncology therapeutics** (100%) — Investigational cancer drug candidates being advanced through clinical trials. - PIKTOR oral combination therapy for oncology - Serabelisib-based investigational cancer treatment - Sapanisertib-based investigational cancer treatment - Clinical development of tumor metabolism and signaling therapies - Preclinical and clinical-stage oncology pipeline ## Customers Faeth does not sell commercial products today; its direct counterparties are clinical investigators, trial sites, contract research organizations, and manufacturing partners that support development. If approved, its end customers would be physicians, hospitals, cancer centers, patients, and third-party payors in oncology markets. - **Clinical development partners** (primary) — CROs, investigators, and CMOs that execute trials and supply manufacturing for product candidates. - **Oncology physicians and cancer centers** (primary) — Future prescribers and treatment centers that would adopt approved therapies if clinical data support use. - **Patients with advanced solid tumors** (primary) — Patients in indications such as endometrial and HR+/HER2- breast cancer targeted by the pipeline. - **Third-party payors** (secondary) — Payers that would determine reimbursement and access after regulatory approval. - Clinical trial sites that enroll patients in Faeth studies - CROs that run preclinical and clinical development work - CMOs that manufacture drug product for trials - Physicians and cancer centers as future prescribers - Patients and payors as future users and reimbursers ## Geography Faeth is headquartered in the United States and conducts its development activities through a U.S.-based biotechnology structure. Its clinical and regulatory exposure is centered on the U.S. FDA, while future commercialization could extend to overseas markets if products are approved. - United States is the core operating and regulatory base - FDA oversight is central to clinical and commercialization plans - Future product sales could extend to overseas markets - Supplier and manufacturing exposure can include China-based inputs - Clinical trial activity is tied to oncology centers and partners ## Strategy The company’s strategy is to advance PIKTOR through clinical trials and build evidence in specific oncology indications, including endometrial cancer and HR+/HER2- breast cancer. Longer term, it will need either internal commercialization capabilities or external partnerships to market any approved product. - **Advance PIKTOR clinical development** (short-term) — Clinical data are the main value driver for a clinical-stage biotech with no product revenue. - **Secure commercialization pathway** (medium-term) — Any approved product will require sales, marketing, and distribution capabilities or partners. - **Broaden oncology pipeline** (long-term) — A broader pipeline can diversify scientific risk and improve long-term optionality. - Advance PIKTOR through ongoing clinical trials - Generate topline data to support future development decisions - Build evidence in targeted oncology indications - Evaluate commercialization through internal or partnered channels - Expand pipeline around tumor metabolism and signaling biology ## Risks Faeth faces the classic risks of a clinical-stage biotech: trial failure, regulatory delay, and uncertainty around market acceptance even if approval is achieved. It also depends on third parties for manufacturing, raw materials, and commercialization, which creates supply-chain and execution risk across the development cycle. - **Clinical development failure** [high] — Drug candidates may not show sufficient efficacy or safety in trials, which can end programs. - **Regulatory approval risk** [high] — FDA or other regulators may require additional data, delay review, or reject applications. - **Commercialization execution risk** [high] — The company may not build internal sales and marketing capabilities or secure effective partners. - **Supplier and manufacturing dependence** [medium] — Clinical materials and specialty inputs are sourced through third parties with limited redundancy. - **China supply-chain exposure** [medium] — Some suppliers or sub-suppliers are based in China, increasing geopolitical and trade risk. - Clinical trials may fail, delay, or produce inconclusive results - FDA approval is uncertain and can be slower than competitors - Commercial launch depends on sales and distribution capabilities - Third-party suppliers and CMOs can disrupt development timelines - China-linked raw materials create trade and supply-chain exposure ## Accounting As a clinical-stage biotech, Faeth’s reported results are driven by research and development expense, stock-based compensation, and fair-value judgments around acquired in-process R&D. The acquisition of Faeth Therapeutics also introduced a large acquired IPR&D charge, which is a key non-cash accounting item investors should separate from operating performance. - **Acquired in-process research and development** — Can materially distort period-to-period comparability - **Research and development expense timing** — Quarterly results can be volatile based on trial activity - **Stock-based compensation** — Affects operating loss and non-cash expense profile - **Fair value measurement** — Can materially affect balance sheet and earnings - Acquired in-process R&D can create large one-time charges - R&D expense reflects CRO, CMO, and trial spending timing - Stock-based compensation can materially affect operating loss - Fair value estimates drive acquired intangible asset accounting - No product revenue means expense recognition dominates results --- *Last updated: 2026-07-02T19:18:51.923363+00:00*